<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51d6/8488718/488945cb7692/jitc-2021-002955f02.jpg"/> </div> <div class="text-side"> <h1>PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.</h1> <p>Example of a patient with a non-CMR on PET/CT scan but negative biopsy for viable tumor. The patient achieved a partial response to anti-PD-1 therapy. (A, B) shows a hypermetabolic subcutaneous metastasis at the left calf pretreatment and 1-year post-treatment with anti-PD-1 therapy. The patient underwent excisional biopsy of the residual left calf lesion. (C) shows pathology findings of excised lesion on H&amp;E stain. Fibrosis, brown pigmented cells considered melanophages and no viable tumor cells identified. (D) shows higher power view of fibrosis and melanophages. (E) shows brown stain with anti-CD68, highlighting melanophages. Additional stains showed melanophages positive for melan-A and fontana mason, but negative for iron (data not shown). CMR, complete metabolic response; PD-1, programmed cell death protein 1.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34599027/" target="_blank">34599027</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>